Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease Emeryville, Calif., June 18, 2013 - Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102
Adamas Pharmaceuticals Announces Issuance of First US Patent for Nurelin™ (Amantadine HCL ER) Program Emeryville, Calif., April 22, 2013 - Adamas Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No.
Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data from Its Nurelin™ Program at American Academy of Neurology Conference Emeryville, Calif., March 20, 2013 - Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin™ (amantadine HCl extended release capsules)
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer’s Disease NEW YORK & EMERYVILLE, CA, November 13, 2012 - Forest Laboratories, Inc.
Adamas Pharmaceuticals Presents Update On NurelinTM Program At Cambridge Healthtech Institute’s Parkinson’s Conference. EMERYVILLE, CALIF., June 4, 2012 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its NurelinTM (amantadine HCl extended
Adamas Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For ARIMENDATM EMERYVILLE, CALIF., May 15, 2012 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the proposed safety and efficacy
Adamas Pharmaceuticals Initiates A Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease EMERYVILLE, CALIF., September 28, 2011 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug